Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
What Does NBA 2K24 Stability Mean?
How to unblock SBS On Demand for free
911 workers say centers are understaffed, struggling to hire and plagued by burnout
Instagram might make it harder for you to send an unsolicited dick pic
Score a like-new Dell Latitude laptop for $450 and get a bonus lifetime license to Microsoft Office
Bills QB Allen basks in celebrity and football, while trying to maintain some semblance of privacy
WWDC 2023: Apple takes on mental health with new iOS 17
'AI doctor' better at predicting patient outcomes, including death